发明申请
- 专利标题: Pyrimidine derivatives
- 专利标题(中): 嘧啶衍生物
-
申请号: US10590707申请日: 2005-02-25
-
公开(公告)号: US20070197551A1公开(公告)日: 2007-08-23
- 发明人: Michitaka Sato , Teruaki Matsui , Akira Asagarasu , Hiroyuki Hayashi , Sei-ichi Araki , Satoru Tamaoki , Nobuyuki Takahashi , Yukinao Yamauchi , Yoshiko Yamamoto , Norio Yamamoto , Chisato Ogawa
- 申请人: Michitaka Sato , Teruaki Matsui , Akira Asagarasu , Hiroyuki Hayashi , Sei-ichi Araki , Satoru Tamaoki , Nobuyuki Takahashi , Yukinao Yamauchi , Yoshiko Yamamoto , Norio Yamamoto , Chisato Ogawa
- 优先权: JP2004-52040 20040226; JP2004-322858 20041105
- 国际申请: PCT/JP05/03691 WO 20050225
- 主分类号: A61K31/497
- IPC分类号: A61K31/497 ; C07D239/06
摘要:
This invention provides pyrimidine derivatives represented by a formula, in the formula, ring A stands for carbocyclic group or heterocyclic group, X1 stands for hydrogen, lower alkyl, amino, etc., X2 stands for hydrogen or lower alkyl, Y stands for a direct bond or sulfur or nitrogen, n stands for an integer of 0-4, and Ar stands for a group of the following formula, or a salt thereof, which concurrently exhibit 5-HT1A agonistic activity and 5-HT3 antagonistic activity and are useful for therapy and treatments of diseases such as IBS. The invention furthermore provides a therapeutic method of IBS, characterized by having 5-HT1A agonistic activity and 5-HT3 antagonistic activity work simultaneously and cooperatively in vivo, which comprises either administering 5-HT3 antagonistic agent which concurrently exhibits 5-HT1A agonistic activity, or administering 5-HT1A agonistic agent and 5-HT3 antagonistic agent simultaneously, in sequence or at an interval.
公开/授权文献
- US07799775B2 Pyrimidine derivatives 公开/授权日:2010-09-21
信息查询
IPC分类: